首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1695709篇
  免费   126785篇
  国内免费   3807篇
耳鼻咽喉   21779篇
儿科学   55773篇
妇产科学   46410篇
基础医学   241731篇
口腔科学   48876篇
临床医学   151660篇
内科学   333882篇
皮肤病学   38735篇
神经病学   131366篇
特种医学   63979篇
外国民族医学   242篇
外科学   257791篇
综合类   39041篇
现状与发展   4篇
一般理论   533篇
预防医学   124247篇
眼科学   40277篇
药学   123959篇
  7篇
中国医学   4552篇
肿瘤学   101457篇
  2021年   12914篇
  2019年   13649篇
  2018年   20114篇
  2017年   15313篇
  2016年   16718篇
  2015年   19125篇
  2014年   26384篇
  2013年   38210篇
  2012年   53153篇
  2011年   55800篇
  2010年   32972篇
  2009年   30892篇
  2008年   51839篇
  2007年   55077篇
  2006年   55545篇
  2005年   52780篇
  2004年   50975篇
  2003年   48340篇
  2002年   46523篇
  2001年   91856篇
  2000年   93685篇
  1999年   77017篇
  1998年   19744篇
  1997年   17308篇
  1996年   17413篇
  1995年   16755篇
  1994年   15305篇
  1993年   14085篇
  1992年   57439篇
  1991年   55308篇
  1990年   53013篇
  1989年   50781篇
  1988年   46153篇
  1987年   44957篇
  1986年   42252篇
  1985年   40016篇
  1984年   29368篇
  1983年   24921篇
  1982年   13910篇
  1979年   25542篇
  1978年   17585篇
  1977年   14914篇
  1976年   13876篇
  1975年   14564篇
  1974年   17633篇
  1973年   16947篇
  1972年   15676篇
  1971年   14458篇
  1970年   13439篇
  1969年   12522篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
2.
Die Anaesthesiologie - Auch wenn für Anästhesiologen über Jahrzehnte die Prophylaxe und Therapie postoperativer Schmerzen im Rahmen des postoperativen Patientenkomforts an vorderster...  相似文献   
3.
4.
5.
6.
7.
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing.  相似文献   
8.
9.
Lessons Learned
  • SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
  • This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
  • SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
BackgroundSCB01A, a novel microtubule inhibitor, has vascular disrupting activity.MethodsIn this phase I dose‐escalation and extension study, patients with advanced solid tumors were administered intravenous SCB01A infusions for 3 hours once every 21 days. Rapid titration and a 3 + 3 design escalated the dose from 2 mg/m2 to the maximum tolerated dose (MTD) based on dose‐limiting toxicity (DLT). SCB01A‐induced cellular neurotoxicity was evaluated in dorsal root ganglion cells. The primary endpoint was MTD. Safety, pharmacokinetics (PK), and tumor response were secondary endpoints.ResultsTreatment‐related adverse events included anemia, nausea, vomiting, fatigue, fever, and peripheral sensorimotor neuropathy. DLTs included grade 4 elevated creatine phosphokinase (CPK) in the 4 mg/m2 cohort; grade 3 gastric hemorrhage in the 6.5 mg/m2 cohort; grade 2 thromboembolic event in the 24 mg/m2 cohort; and grade 3 peripheral sensorimotor neuropathy, grade 3 elevated aspartate aminotransferase, and grade 3 hypertension in the 32 mg/m2 cohort. The MTD was 24 mg/m2, and average half‐life was ~2.5 hours. The area under the curve‐dose response relationship was linear. Nineteen subjects were stable after two cycles. The longest treatment lasted 24 cycles. SCB01A‐induced neurotoxicity was reversible in vitro.ConclusionThe MTD of SCB01A was 24 mg/m2 every 21 days; it is safe and tolerable in patients with solid tumors.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号